| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | bioA |
| Uniprot No | P12995 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-429aa |
| 氨基酸序列 | MTTDDLAFDQRHIWHPYTSMTSPLPVYPVVSAEGCELILSDGRRLVDGMSSWWAAIHGYNHPQLNAAMKSQIDAMSHVMFGGITHAPAIELCRKLVAMTPQPLECVFLADSGSVAVEVAMKMALQYWQAKGEARQRFLTFRNGYHGDTFGAMSVCDPDNSMHSLWKGYLPENLFAPAPQSRMDGEWDERDMVGFARLMAAHRHEIAAVIIEPIVQGAGGMRMYHPEWLKRIRKICDREGILLIADEIATGFGRTGKLFACEHAEIAPDILCLGKALTGGTMTLSATLTTREVAETISNGEAGCFMHGPTFMGNPLACAAANASLAILESGDWQQQVADIEVQLREQLAPARDAEMVADVRVLGAIGVVETTHPVNMAALQKFFVEQGVWIRPFGKLIYLMPPYIILPQQLQRLTAAVNRAVQDETFFCQ |
| 预测分子量 | 54.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于bioA重组蛋白的虚构参考文献示例，涵盖不同研究方向：
1. **文献名称**：*Heterologous Expression and Characterization of Recombinant bioA from Mycobacterium tuberculosis*
**作者**：Chen L, et al.
**摘要**：研究报道了结核分枝杆菌bioA基因在大肠杆菌中的重组表达与纯化，分析了其酶活性及在生物素合成途径中的作用，为针对该靶点的抗结核药物开发提供基础数据。
2. **文献名称**：*Crystal Structure of bioA-Encoded 7.8-Diaminopelargonic Acid Aminotransferase*
**作者**：Smith JR, et al.
**摘要**：通过X射线晶体学解析了bioA重组蛋白的三维结构，揭示了其底物结合位点及催化机制，为基于结构的抑制剂设计提供了依据。
3. **文献名称**：*Targeting bioA in Staphylococcus aureus: A Novel Strategy for Antibiotic Development*
**作者**：Wang Y, et al.
**摘要**：探讨了金黄色葡萄球菌bioA作为抗菌药物靶点的潜力，通过体外实验验证了抑制bioA可阻断细菌生物素合成，显著抑制病原体生长。
4. **文献名称**：*Metabolic Engineering of bioA in Bacillus subtilis for Enhanced Biotin Production*
**作者**：Kim H, et al.
**摘要**：通过重组表达优化和调控bioA表达水平，显著提高了枯草芽孢杆菌的生物素产量，为工业微生物生产生物素提供了新策略。
(注：以上文献为示例性内容，实际研究中需查阅真实数据库获取有效参考文献。)
BioA, also known as 7-keto-8-aminopelargonic acid (KAPA) synthase or Dethiobiotin Synthetase, is a critical enzyme in the biotin (vitamin B7) biosynthesis pathway. It catalyzes the conversion of 7-keto-8-aminopelargonic acid (KAPA) to dethiobiotin (DTB), a penultimate step in biotin production. This pathway is essential for microorganisms, plants, and some fungi, but absent in mammals, making BioA a potential antimicrobial drug target. Recombinant BioA protein refers to the enzyme produced through genetic engineering techniques, typically expressed in heterologous systems like *E. coli*, yeast, or mammalian cells.
The interest in recombinant BioA stems from its dual significance in basic research and applied sciences. Structurally, BioA belongs to the PLP-dependent enzyme family, utilizing pyridoxal 5'-phosphate as a cofactor. Its catalytic mechanism and substrate specificity have been studied to elucidate biotin biosynthesis regulation. Recombinant versions enable high-purity protein production for crystallography, enzymatic assays, and inhibitor screening. In drug discovery, BioA inhibitors are explored to combat pathogens like *Mycobacterium tuberculosis* and *Staphylococcus aureus*, where biotin auxotrophy renders the enzyme indispensable for survival.
Industrial applications include optimizing biotin production in engineered microbes. Challenges in recombinant BioA production involve achieving proper folding and solubility, often addressed through codon optimization, fusion tags, or chaperone co-expression. Recent advances in structural biology and computational modeling have accelerated the characterization of BioA variants and inhibitor design. Additionally, recombinant BioA serves as a tool enzyme in metabolic engineering to reconstruct biotin pathways in non-native hosts. Its study bridges fundamental biochemistry with translational applications in antimicrobial therapy and industrial biotechnology.
×
